Displaying items by tag: UAB Comprehensive Diabetes Center

UAB Heersink School of Medicine staff council representatives have officially been named for the 2022-2024 term. See who has been elected to represent you!
Inhibition of this microRNA might improve response to newer diabetes drugs, such as Byetta, Victoza, Trulicity, Januvia, Onglyza and Tradjenta.
Recruitment for the trial continues as Myers discusses the benefits she received from participating and the knowledge she has gained to take control of her health care.
Lead author of paper published in Diabetes Research and Clinical Practice journal says, while causal relationship cannot be inferred, findings are “absolutely encouraging.”
Many patients diagnosed with type 1 diabetes as adults do not fit the standard profile for a diabetes diagnosis; they are younger, are relatively fit and have little if any belly fat.
Three-year grant establishes consortium to better organize and support collaborative research related to the loss of functional beta cell mass in type 1 diabetes.
The “repurposing of verapamil as a beta cell survival therapy in type 1 diabetes” trial will test an approach different from any current diabetes treatment.
African-Americans have higher obesity rates than do whites, and while socioeconomic status is often believed to be the root cause, a new UAB study suggests other factors should be considered.
Page 1 of 2